Clinical trial
A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing…
NCT00071799 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00071799 |
|---|---|
| Title | A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care |
| Official title | A Multicenter, Randomized, Open-label, Parallel-group, Phase 3 Trial of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes (MDS) |
| Lead sponsor | Celgene, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes |
| Intervention type | Drug, Other |
| Interventions | Azacitidine, Physician Choice |
| Enrollment | 358 |
| Start date | Nov 1, 2003 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Nov 5, 2003 |
| Last update posted | Oct 29, 2019 |
| Countries | Australia, Bulgaria, Czechia, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, Russia, Spain and 3 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: